W911QX22F0029↗
Fibertek, Inc. received this contract from W6QK Acc-Apg Adelphi, Department of the Army: $16.49M obligated so far for national defense r&d services; department of defense - military; basic research. Its period of performance ended 2025-03-26.
Key facts · data as of Oct 22, 2026
- Recipient
- Fibertek, Inc.
- Awarding agency
- Department of the Army (Department of Defense)
- Contracting office
- W6QK Acc-Apg Adelphi (W911QX)
- Obligated to date
- $16.49M
- Potential value
- $20.61M
- Ends
- 2025-03-26
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 22, 2026.
Cite this page: SpendQuery, Award W911QX22F0029, data as of Oct 22, 2026, https://spendquery.com/award?id=CONT_AWD_W911QX22F0029_9700_W15P7T19D0038_9700
Fibertek, Inc.: all federal awards · Department of Defense: spending · W6QK Acc-Apg Adelphi: what it buys
BATTLEFIELD R&D, ANALYSIS AND VERIFICATION EXPERIMENTATION (BRAVE) SERVICES.
Obligated to date$16.49M23 actions
Current value$20.61Mwith options exercised
Period2022-07-01 → 2025-03-26current end date
What it is
- Product or service
- National Defense R&D Services; Department of Defense - Military; Basic Research (PSC AC11)
- Industry
- Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) (NAICS 541715)
- Contracting office
- W6QK Acc-Apg Adelphi (W911QX)
- Competition
- Full and open competition · 1 offer received
- Set-aside
- Small business
- Pricing
- Cost plus fixed fee
- How it was bought
- Multiple-award IDIQ · under W15P7T19D0038
- Solicitation
- W911QX22R0005
- Where the work is
- Prince Georges, MD · district MD-04
Obligations by fiscal year
FY2023$8.03M
FY2024$8.46M
FY2025$0
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
Every action
23 actions since 2022-11-25. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2025-03-05 | P00025 | Administrative change | $0 | BATTLEFIELD RESEARCH & DEVELOPMENT, ANALYSIS AND VERIFICATION EXPERIMENTATION (BRAVE) SERVICES. |
| 2024-09-23 | P00024 | Funding only | $495.1K | BATTLEFIELD R&D, ANALYSIS AND VERIFICATION EXPERIMENTATION (BRAVE) SERVICES. INCREMENTAL FUNDING MODIFICATION: CLIN 1002 & 1006. |
| 2024-08-22 | P00023 | Funding only | $1.69M | BATTLEFIELD R&D, ANALYSIS AND VERIFICATION EXPERIMENTATION (BRAVE) SERVICES. INCREMENTAL FUNDING MODIFICATION: CLIN 1002 & 1005. |
| 2024-07-19 | P00022 | Funding only | $3.24M | BATTLEFIELD R&D, ANALYSIS AND VERIFICATION EXPERIMENTATION (BRAVE) SERVICES. INCREMENTAL FUNDING MODIFICATION: CLINS 1002, 1004 & 1005. |
| 2024-05-07 | P00021 | Supplemental agreement (work within scope) | $0 | BATTLEFIELD R&D, ANALYSIS AND VERIFICATION EXPERIMENTATION (BRAVE) SERVICES. THIS MODIFICATION EXTENDS CONTRACT CEILING ON CLINS 1002, 1004 AND 1005 TO EXTEND THE BUYING PERIOD. |
| 2024-04-25 | P00020 | Supplemental agreement (work within scope) | $1.21M | BATTLEFIELD R&D, ANALYSIS AND VERIFICATION EXPERIMENTATION (BRAVE) SERVICES, INCREMENTAL FUNDING MODIFICATION: CLIN 1002 AND 1005. SHIFT CONTRACT CEILING OF $250,000.00 FROM CLIN 1004 TO CLIN 1005. |
| 2024-03-05 | P00019 | Funding only | $727.5K | BATTLEFIELD R&D, ANALYSIS AND VERIFICATION EXPERIMENTATION (BRAVE) SERVICES. INCREMENTAL FUNDING MODIFICATION: CLIN 1002. |
| 2024-01-08 | P00018 | Supplemental agreement (work within scope) | $157.4K | MODIFICATION TO CORRECT A TYPOGRAPHICAL ERROR IN BOX 14(A) ON P00017 WITH THE AMOUNT OF FUNDING BEING ADDED TO THE BRAVE SERVICES CONTRACT. ADDITIONALLY TO INCREMENTALLY FUND CLIN 1002 BY $157,407.00 TO FUND PERFORMANCE UNTIL 29 FEB 2024 |
| 2023-12-21 | P00017 | Funding only | $415.2K | INC FUNDING MODIFICATION TO CLIN 1002 FOR CONTINUED PERFORMANCE UNDER BRAVE |
| 2023-11-22 | P00016 | Supplemental agreement (work within scope) | $523.7K | BATTLEFIELD R&D, ANALYSIS AND VERIFICATION EXPERIMENTATION (BRAVE) SERVICES. INCREMENTAL FUNDING MODIFICATION TO FUND CLINS 0002, 0005 & 1002. EXTEND THE PERIOD OF PERFORMANCE ON CLINS 0002, 0004 AND 0005. |
| 2023-10-20 | P00015 | Supplemental agreement (work within scope) | $0 | BATTLEFIELD R&D, ANALYSIS AND VERIFICATION EXPERIMENTATION (BRAVE) SERVICES. MODIFICATION TO CORRECT CONTRACT CEILING ON CLIN 0002 & CORRECT NARRATIVE REGARDING PERIOD OF PERFORMANCE. |
| 2023-09-29 | P00014 | Supplemental agreement (work within scope) | $934.2K | BATTLEFIELD R&D, ANALYSIS AND VERIFICATION EXPERIMENTATION (BRAVE) SERVICES. MODIFICATION TO SHIFT CONTRACT CEILING FROM CLINS 0004 7 0005 TO CLIN 0002 AND INCREMENTALLY FUND CLIN 0002 CLIN 1002 AND CLIN 1005. |
| 2023-09-28 | P00013 | Option exercised | $2.60M | BATTLEFIELD R&D, ANALYSIS AND VERIFICATION EXPERIMENTATION (BRAVE) SERVICES, MODIFICATION TO EXERCISE OPTIONS AND INCREMENTALLY FUND CLINS 1002, 1004 AND 1005. |
| 2023-09-08 | P00012 | Supplemental agreement (work within scope) | $458.9K | BATTLEFIELD R&D, ANALYSIS AND VERIFICATION EXPERIMENTATION (BRAVE) SERVICES. MODIFICATION TO INCREMENTALLY FUND CLIN 0002 & ADD FAR CLAUSE 52.204-27. |
| 2023-08-04 | P00011 | Supplemental agreement (work within scope) | $494.0K | BATTLEFIELD R&D, ANALYSIS AND VERIFICATION EXPERIMENTATION (BRAVE) SERVICES. MODIFICATION TO INCREMENTALLY FUND CLIN 0002. |
| 2023-06-26 | P00010 | Supplemental agreement (work within scope) | $125.4K | BATTLEFIELD R&D, ANALYSIS AND VERIFICATION EXPERIMENTATION (BRAVE) SERVICES. MODIFICATION TO ADD TEXT TO CLIN 0002/SLIN 000234, INCREMENTALLY FUND CLIN 0002, INCORPORATE DD FORM 254 & EXTEND PERIOD OF PERFORMANCE. |
| 2023-05-15 | P00009 | Funding only | $1.36M | BATTLEFIELD R&D, ANALYSIS AND VERIFICATION EXPERIMENTATION (BRAVE) SERVICES. MODIFICATION TO SHIFT CEILING FROM CLIN 0004 TO CLIN 0005 AND INCREMENTALLY FUND CLINS 0002 & 0005 |
| 2023-05-04 | P00008 | Funding only | $415.0K | BATTLEFIELD R&D, ANALYSIS AND VERIFICATION EXPERIMENTATION (BRAVE) SERVICES. MODIFICATION TO OBLIGATE FUNDING (CLIN 0002). |
| 2023-05-03 | P00007 | Funding only | -$415.0K | BATTLEFIELD R&D, ANALYSIS AND VERIFICATION EXPERIMENTATION (BRAVE) SERVICES. MODIFICATION TO DE-OBLIGATE FUNDING FROM CLIN 0004. |
| 2023-05-01 | P00006 | Funding only | $415.0K | BATTLEFIELD R&D, ANALYSIS AND VERIFICATION EXPERIMENTATION (BRAVE) SERVICES. INCREMENTAL FUNDING MODIFICATION: CLIN 0004. |
| 2023-03-01 | P00005 | Funding only | $1.12M | BATTLEFIELD R&D, ANALYSIS AND VERIFICATION EXPERIMENTATION (BRAVE) SERVICES. INCREMENTAL FUNDING MODIFICATION CLIN 0002. |
| 2022-12-02 | P00004 | Funding only | $92.5K | BATTLEFIELD R&D, ANALYSIS AND VERIFICATION EXPERIMENTATION (BRAVE) SERVICES. INCREMENTAL FUNDING MODIFICATION: CLIN 0002 |
| 2022-11-25 | P00003 | Funding only | $426.4K | BATTLEFIELD R&D, ANALYSIS AND VERIFICATION EXPERIMENTATION (BRAVE) SERVICES. INCREMENTALLY FUND CLIN 0002 AND 0005. |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-22). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗